Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
07:30am, Friday, 08'th Mar 2024
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dos
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
07:30am, Monday, 04'th Mar 2024
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
06:30am, Sunday, 25'th Feb 2024
Investors may want to jump into oversold Russell 2000 stocks. For one, after a rough outing in 2023, smaller-cap stocks are starting to come back strong.
7 Biotech Stocks Fighting America's Deadliest Diseases
04:10pm, Thursday, 08'th Feb 2024
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2024 Earnings Call Transcript
09:28pm, Tuesday, 06'th Feb 2024
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
04:01pm, Tuesday, 06'th Feb 2024
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023. The Company is
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
04:01pm, Monday, 22'nd Jan 2024
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discu
Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
08:47am, Sunday, 21'st Jan 2024
Arrowhead Pharmaceuticals lacks focus with a pipeline of 16 programs, hindering its progress in bringing a product to market. The company has experienced setbacks, including poor data from ARO-AAT and
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
05:00pm, Friday, 05'th Jan 2024
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering
Arrowhead Pharmaceuticals: Transition To Commercialization
12:26pm, Thursday, 07'th Dec 2023
Arrowhead Pharmaceuticals is transitioning from a pre-commercialization phase to a fully commercial pharmaceutical company. The company is focused on bringing candidate drugs in varied disease categor
Arrowhead Pharma offers 'an attractive mix' of early and late-stage programs, analysts say
03:54pm, Monday, 04'th Dec 2023
Arrowhead Pharma shares rose more than 5% Monday afternoon to $24.41 after Bank of America analysts initiated overage of the company with a Buy rating and price target of $29. The clinical-stage bio
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2023 Earnings Call Transcript
08:27pm, Wednesday, 29'th Nov 2023
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q4 2023 Earnings Conference Call November 29, 2023 4:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - P
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2023 Earnings Call Transcript
06:35pm, Monday, 07'th Aug 2023
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - Pres
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results
04:00pm, Monday, 24'th Jul 2023
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m. ET to discuss
Arrowhead: Biotech Innovation On Display
11:55am, Tuesday, 06'th Jun 2023
Arrowhead is a promising biotech company with a strong platform and pipeline of drugs targeting various diseases. Arrowhead has expanded its focus from liver disease to cardiovascular, pulmonary and c
